Trial Profile
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Both plus Mealtime Insulin in Patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EDITION-I
- Sponsors Sanofi
- 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 08 Dec 2017 Results of a post-hoc analysis from EDITION 1,2, and 3 studies presented at the 2017 Congress of the International Diabetes Federation.
- 08 Dec 2017 Results from EDITION 1,2, and 3 studies presented at the 2017 Congress of the International Diabetes Federation.